Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 8/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25195104 | 1.00 | MAPT (0.66) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL25195488 | 1.00 | MAPT (0.66) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL11459733 | 0.87 | KMT2A (0.75) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL11459734 | 0.87 | KMT2A (0.75) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL25208390 | 0.85 | KMT2A (0.56) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL25214787 | 0.84 | NPC1 (0.71) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL25194910 | 0.83 | MAOB (0.77) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL25206233 | 0.83 | MAOB (0.75) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL25217929 | 0.83 | MAOB (0.75) | MAPTKMT2ARAB9AMEN1NPC1 | |
| SCHEMBL25202067 | 0.83 | MAOB (0.77) | MAPTKMT2ARAB9AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885KMT2A 3188/4885RAB9A 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.